FDA lays out donanemab concerns ahead of meeting, as Lilly vigorously defends safety

The docs for Eli Lilly’s donanemab advisory committee meeting are in: the FDA has raised concerns about the use of tau PET imaging during the clinical trials, the cessation of dosing after amyloid clearance and whether the small risk of brain bleeds in patients taking antithrombotics outweighs the benefits.